In Brasilia, our Commerce Secretary just pushed Brazil for a simpler, more predictable system to sell Indian medicines. Why? Because pharma isn’t just a sector; it’s a lifeline for millions abroad, and a ₹50,000 crore+ export opportunity waiting to explode. With trade between India & Brazil already at $15B, the goal is $30B by 2030; and pharma is central to that plan. Behind the scenes, Indian firms like UPL and Kirloskar are already on the ground, paving the way. This isn’t just diplomacy; it’s business strategy baked into government policy. And if you’re preparing for UPSC, RBI Grade B, or even CAT; remember: trade deals don’t happen in vacuum. They’re built on regulatory clarity, market access, and patient persistence. The next big exam question? Probably this.